|
1) 林三千雄, 春田恒和. 新型インフルエンザに関するレポート(神戸市立医療センター中央市民病院感染管理室報告). 日本感染症学会. http://www.kansensho.or.jp/, 2009年5月20日
|
|
|
|
|
2) 山本 剛, 大寺 博, 熊木まゆ子 他. 西神戸医療センターでの新型インフルエンザの報告. 日本感染症学会. http://www.kansensho.or.jp/, 2009年5月22日
|
|
|
|
|
|
3) Schunemann HJ, Hill SR, Kakad M, et al. WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus. Lancet Infect Dis. 2007; 7: 21-31
|
|
|
|
|
4) Kidd IM, Down J, Nastouli E, et al. H1N1 pneumonitis treated with intravenous zanamivir. Lancet 2009; 374: 1036
|
|
|
|
|
|
5) Härter G, Zimmermann O, Maier L, et al. Intravenous zanamivir for patients with pneumonitis due to pandemic (H1N1) 2009 influenza virus. Clin Infect Dis. 2010; 50: 1249-51
|
|
|
|
|
|
6) Beigel J, Bray M. Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral Res. 2008; 78: 91-102
|
|
|
|
|
|
7) 渡辺 彰. タミフルⓇ・リレンザⓇに続く新規インフルエンザ治療薬の開発～仙台方式の紹介を含めて～. 日内会誌. 2009; 98: 2576-80
|
|
|
|
|
|
8) Hurt AC, Selleck P, Komadina N, et al. Susceptibility of highly pathogenic A (H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes. Antiviral Res. 2007; 73: 228-31
|
|
|
|
|
|
9) Yun NE, Linde NS, Zacks MA, et al. Injectable peramivir mitigates disease and promotes survival in ferrets and mice infected with highly virulent influenza virus A/Vietnam/1203/04(H5N1). Virology. 2008; 374: 198-209
|
|
|
|
|
|
10) Itoh Y, Shinya K, Kiso M, et al. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature. 2009; 460: 1021-5
|
|
|
|
|
|
11) Sidwell RW, Barnard DL, Day CW, et al. Efficacy of orally administered T‐705 on lethal avian influenza A(H5N1) virus infections in mice. Antimicrob Agents Chemother. 2007; 51: 845-51
|
|
|
|
|
|
12) Chan RW, Chan MC, Wong AC, et al. DAS181 inhibits H5N1 influenza virus infection of human lung tissues. Antimicrob Agents Chemother. 2009; 53: 3935-41
|
|
|
|
|
|
13) Castillo R, Holland LE, Boltz DA. Peramivir and its use in H1N1 influenza. Drugs Today (Barc). 2010; 46: 399-408
|
|
|
|
|
|
14) Sleeman K, Mishin VP, Deyde VM, et al. In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A (H1N1) viruses. Antimicrob Agents Chemother. 2010; 54: 2517-24
|
|
|
|
|
|
15) Triana-Baltzer GB, Gubareva LV, Nicholls JM, et al. Novel pandemic influenza A (H1N1) viruses are potently inhibited by DAS181, a sialidase fusion protein. PLoS One. 2009; 4: e7788
|
|
|
|
|
|
16) Bantia S, Arnold CS, Parker CD, et al. Anti-influenza virus activity of peramivir in mice with single intramuscular injection. Antiviral Res. 2006; 9: 39-45
|
|
|
|
|
|
17) Hayden F. Developing new antiviral agents for influenza treatment: What does the future hold？ Clin Infect Dis. 2009; 48(Suppl. 1): S3-S13
|
|
|
|
|
|
18) Yamashita M, Tomozawa T, Kakuta M, et al. CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. Antimicrob Agents Chemother. 2009; 53: 186-92
|
|
|
|
|
|
19) Koyama K, Takahashi M, Oitate M, et al. CS-8958, a prodrug of the novel neuraminidase inhibitor R-125489, demonstrates a favorable long-retention profile in the mouse respiratory tract. Antimicrob Agents Chemother. 2009; 53: 4845-51
|
|
|
|
|
|
20) Sidwell RW, Bailey KW, Wong MH, et al. In vitro and in vivo influenza virus-inhibitory effects of viramidine. Antiviral Res. 2005; 68: 10-17
|
|
|
|
|
|
21) Furuta Y, Takahashi K, Kuno‐Maekawa M, et al. Mechanism of action of T‐705 against influenza virus. Antimicrob Agents Chemother. 2005; 49: 981-6
|
|
|
|
|
|
22) Furuta Y, Takahashi K, Fukuda Y, et al. In vitro and in vivo activities of anti‐influenza virus compound T‐705. Antimicrob Agents Chemother. 2002; 46: 977-81
|
|
|
|
|
|
23) Furuta Y, TakahashiK, Shiraki K, et al. Review; T-705 (Favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections. Antiviral Research. 2009; 82: 95-102
|
|
|
|
|
|
24) Zhou H, Jin M, Yu Z, et al. Effective small interfering RNAs targeting matrix and nucleocapsid protein gene inhibit influenza A virus replication in cells and mice. Antiviral Res. 2007; 76: 186-93
|
|
|
|
|
|
25) Wu Y, Zhang G, Li Y, et al. Inhibition of highly pathogenic avian H5N1 influenza virus replication by RNA oligonucleotides targeting NS1 gene. Biochem Biophys Res Commun. 2008; 365: 369-74
|
|
|
|
|
|
26) Malakhov MP, Aschenbrenner LM, Smee DF, et al. Sialidase fusion protein as a novel broad‐spectrum inhibitor of influenza virus infection. Antimicrob Agents Chemother. 2006; 50: 1470-9
|
|
|
|
|
|
27) Hedlund M, Aschenbrenner LM, Jensen K, et al. Sialidase-based anti-influenza virus therapy protects against secondary pneumococcal infection. J Infect Dis. 2010; 201: 1007-15
|
|
|
|
|
|
28) Triana-Baltzer GB, Babizki M, Chan MC, et al. DAS181, a sialidase fusion protein, protects human airway epithelium against influenza virus infection: an in vitro pharmacodynamic analysis. J Antimicrob Chemother. 2010; 65: 275-84
|
|
|
|
|
|
29) CDC. Update: Drug susceptibility of swine-origin influenza virus A (H1N1) viruses, April 2009. MMWR. 2009; 58: 433-5
|
|
|
|
|
|
30) Sugaya N, Ohashi N. Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection. Antimicrob Agents Chemother. 2010; 54: 2575-82
|
|
|
|
|
|
31) 日本感染症学会新型インフルエンザ対策委員会. 社団法人日本感染症学会提言 2010-01-25～新規薬剤を含めた抗インフルエンザ薬の使用適応について～. 日本感染症学会. http://www.kansensho.or.jp/. 2010年1月25日
|
|
|
|
|
|
32) Falagas ME, Koletsi PK, Vouloumanou EK, et al. Effectiveness and safety of neuraminidase inhibitors in reducing influenza complications: a meta-analysisi of randomized controlled trials. J Antimicrob Chemother. 2010; 65: 1330-46
|
|
|
|
|